Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Analysts at Atb Cap Markets boosted their FY2025 earnings estimates for Bradmer Pharmaceuticals in a report issued on Tuesday, May 20th. Atb Cap Markets analyst M. Toner now expects that the company will earn $1.12 per share for the year, up from their prior forecast of ($0.97). Atb Cap Markets also issued estimates for Bradmer Pharmaceuticals’ FY2026 earnings at ($4.46) EPS.
GLX has been the subject of a number of other reports. BTIG Research raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, April 14th. Cantor Fitzgerald raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Tuesday, February 25th. Finally, Benchmark raised shares of Bradmer Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 31st.
Bradmer Pharmaceuticals Stock Performance
Featured Stories
- Five stocks we like better than Bradmer Pharmaceuticals
- How to Effectively Use the MarketBeat Ratings Screener
- Turbulence for Joby Shares: What’s Behind the Recent Dip?
- How to trade using analyst ratings
- Why Carnival Could Be the Ultimate Non-Tech Growth Stock
- How Can Investors Benefit From After-Hours Trading
- Super Micro Computer Stock Clears New Path Higher on Saudi Orders
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
